Introduction
showed temporary tumor-growth inhibition only [4] , Head and neck squamous cell carcinoma (HNSCC) The efficacy of locoregional injections with low doses appears to be a suitable disease in which to evaluate of interleukin-2 (IL-2) has been described in several local IL-2 immunotherapy in man. This tumor is localexperimental tumors. Besides locoregional antitumor izecl near the body surface, close to submucosal and effects, this approach has been shown to induce spe-nodular lymphatic tissue, and tends to recur loco regionally after primary therapy, Cortesina et al. [6, 7] obtained objective responses with perilymphatic IL-2 (i.e., around the tumor-draining lymph cific systemic immunity, which resulted in rejection of tumor cells inoculated at distant sites |l~-3|, The peritumoral administration route of IL-2 and the presence of lymphocytes at the tumor site appeared to be pre-nodes) in locoregionally recurrent HNSCC (6/10 and requisites for these effects. It was hypothesized that 4/31 patients). We could not confirm this in patients host immune cells at the tumor site were activated by with primary locoregionally far-advanced disease [8j. exogenous IL-2 to produce cytokines and to recruit Partial responses were also described in HNSCC paspecific and nonspecific immune effector mechanisms dents using combined perilymphatic and intratumoral , We analyzed locoregional immunotherapy in the IL-2 injections (2/36 patients) [9] , intra-arterial IL-2 guinea pig line-10 tumor model |4j. In addition to IL-2, polyethylene glycol (PEG)-modificd IL-2 was also infusion (2/12 pi 10], and combined locore gional IL-2 and LÀK cell administration (3/14 pauscd, enhancing solubility and plasma half-life [5] , tients) [11] , The aim of the present study was to evalu-It was found that guinea-pigs with palpable tumors ate the feasibility and the local antitumor effects of on the flank and micrometastases in the regional intratumoral PEG-IL-2 injections in HNSCC, in a lymph nodes could be cured by intratumoral, but not schedule which had been found to be optimal in our perilymphatic, injections of PEG-IL-2, whereas IL-2 animal study [4] ,
Patients and methods
Nineteen patients ( 13 men, 6 women) with a median age of 69 years (range 46-83), gave informed consent and entered this study. Eli gible patients had to have measurable, histologically-or cytologically-confirmed locoregional recurrence of HNSCC since previous surgery and/or radiotherapy at not more than two sites, for which no curative treatment was available. Tumor recurrences had to be accessible to injection, and could not exceed 8 cm at the largest diameter. Further eligibility criteria included: Karnofsky perfor mance status >70%, expected survival >3 months, normal hema tologic parameters, adequate hepatic, renal, and cardiac function, no other significant medical conditions requiring ongoing therapy, no organ allografts, no concurrent corticosteroid therapy, and no dis tant métastasés. The study was carried out with ethical committee approval.
Recombinant human IL-2 modified by the covalent attachment of 2-3 PEG Mr 7,000 molecules per IL~2 molecule (PEG-IL-2) was provided by EuroCetus, Amsterdam, The Netherlands. Specific activity was 85.7 x 105 (Lotno. LCP-920) or 40.0 x 105 (Lotno, LCP-039B) U/mg IL-2 protein. Intralesional injections with 200,000 U PEG-IL-2 in 0.5 ml normal saline, containing 0.1% human serum albumin, were given 3 times a week for 4 weeks. Patients with 2 tumor recurrences received a double dose. Response to treatment was evaluated after 4 weeks, and defined according to WHO criteria. Patients with progressive disease (PD) were removed from the study, in instances of stable disease (SD) treatment was continued for 8 weeks. Objective responders were scheduled to receive 12 weeks of treatment without interruption. Response dura tion and patient survival were determined from the start of PEG-IL-2 treatment.
Results
In 19 patients 22 tumor recurrences were treated (Table 1) . Prior treatment included radiotherapy (all 19), primary tumor resection (14 patients), neck lymph node dissection (unilateral in 6 and bilateral in 5), and chemotherapy (4 patients). Median time between con clusion of previous treatment and diagnosis of the cur rent tumor recurrence was 4 months. PEG-IL-2 was injected preferably in vital tumor borders, rather than in necrotic central parts. For treatment of lymph node métastasés the injection site and depth were deter mined by ultrasound. Seventeen patients were evalu able for response. One complete response (CR; 6%) was obtained in a man with a subcutaneous metastasis in the neck. Shrinkage of the lesion was first observed after 3 weeks of PEG-IL-2 treatment. After 8 weeks a flat skin lesion remained, which could no longer be injected. Treatment was then stopped, and 4 weeks later the lesion had disappeared completely (Fig. 1) , The CR persisted for 91 weeks. The subsequent tumor recurrence was not accessible to injection. In 6 patients SD was recorded (duration 8-57+ weeks). Patients with progressive tumor growth at evaluation after 4 weeks, or before completing the successive 4 weeks oi treatment were recorded as PD. Two patients were not evaluable for response, one because of unmeasurable disease, and the other because of early death. The lattei occurred in a 66-year~old man who unexpectedly died during his sleep about 36 hours after the 5th PEG-IL-2 administration for 2 skin métastasés on the cheek Autopsy was not permitted and the cause of death re mained uncertain. A relationship with PEG-IL-2 treat ment was considered unlikely. Chemotherapy, given tc 5 patients (Nos. 3, 4, 14, 16 , and 17) for progressive tumor growth following PEG-IL-2 therapy, did no result in objective responses. Median survival from the start of PEG-IL-2 treatment was 23 weeks for the tota group, and 45+ weeks for the 6 patients who achievec SD. 
